April 2024
-
04.26.2024
Prescription Medicines Medicines U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
-
04.25.2024
Corporate Finance Pfizer Announces 2024 Shareholder Meeting Preliminary Results
-
04.24.2024
Corporate Finance Pfizer Declares Second-Quarter 2024 Dividend
-
04.22.2024
Prescription Medicines Medicines European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
-
04.11.2024
-
04.09.2024
March 2024
-
03.20.2024
-
03.13.2024
-
03.12.2024
-
03.05.2024
February 2024
-
02.29.2024
-
02.29.2024